Gregory Scott Duncan

This profile gathers the share dealings of Gregory Scott Duncan across 2 companies, led by Dogwood Therapeutics, Inc. and CorMedix Inc. In total, 10 filings cover trades dated from 6 January 2021 to 26 January 2026.

No open-market sale appears; the market trades are 6 purchases worth €251k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Other entries cover 2 share grants and 2 option exercises.

A typical purchase (the median) is worth €30k. Of 5 purchases, 2 formed part of a group of insiders buying within 30 days of each other. Purchases made close together by different insiders form what is called a cluster.

The newest entry dates from 27 January 2026: a share grant, in CorMedix Inc. The most recent open-market purchase was published on 18 August 2023, 1,163 days ago. The median gap between a trade and its publication by SEC (Form 4) is 1 day. For comparison, the SEC allows two business days to file a Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.